ERBB2 and esophageal squamous cell carcinoma: Moreover, since GRB7 reportedly acts with other tyrosine kinase receptors as well as ERBB2, we expect that inhibition of GRB7 would be a novel therapeutic strategy effective for ESCC patients with resistance to trastuzumab.